首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   1889207篇
  免费   141819篇
  国内免费   4565篇
耳鼻咽喉   24079篇
儿科学   60945篇
妇产科学   50064篇
基础医学   266765篇
口腔科学   52710篇
临床医学   171615篇
内科学   373212篇
皮肤病学   41501篇
神经病学   150237篇
特种医学   70810篇
外国民族医学   253篇
外科学   287831篇
综合类   41797篇
现状与发展   4篇
一般理论   825篇
预防医学   141592篇
眼科学   45319篇
药学   137561篇
  11篇
中国医学   4631篇
肿瘤学   113829篇
  2021年   15465篇
  2019年   17811篇
  2018年   24845篇
  2017年   18837篇
  2016年   20670篇
  2015年   23734篇
  2014年   33297篇
  2013年   47874篇
  2012年   67553篇
  2011年   71127篇
  2010年   41560篇
  2009年   38591篇
  2008年   65298篇
  2007年   69442篇
  2006年   69785篇
  2005年   66957篇
  2004年   64308篇
  2003年   60722篇
  2002年   58119篇
  2001年   93397篇
  2000年   94716篇
  1999年   78391篇
  1998年   20978篇
  1997年   18035篇
  1996年   17934篇
  1995年   18389篇
  1994年   16682篇
  1993年   15302篇
  1992年   58335篇
  1991年   56204篇
  1990年   53754篇
  1989年   51538篇
  1988年   46896篇
  1987年   45713篇
  1986年   42986篇
  1985年   40804篇
  1984年   30352篇
  1983年   25788篇
  1982年   14980篇
  1981年   13419篇
  1979年   26065篇
  1978年   18168篇
  1977年   15368篇
  1976年   14321篇
  1975年   14924篇
  1974年   17997篇
  1973年   17245篇
  1972年   15971篇
  1971年   14677篇
  1970年   13617篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
Modified-release opioids are often prescribed for the management of moderate to severe acute pain following total hip and knee arthroplasty, despite recommendations against their use due to increasing concerns regarding harm. The primary objective of this multicentre study was to examine the impact of modified-release opioid use on the incidence of opioid-related adverse events compared with immediate-release opioid use, among adult inpatients following total hip or knee arthroplasty. Data for total hip and knee arthroplasty inpatients receiving an opioid analgesic for postoperative analgesia during hospitalisation were collected from electronic medical records of three tertiary metropolitan hospitals in Australia. The primary outcome was the incidence of opioid-related adverse events during hospital admission. Patients who received modified with or without immediate-release opioids were matched to those receiving immediate-release opioids only (1:1) using nearest neighbour propensity score matching with patient and clinical characteristics as covariates. This included total opioid dose received. In the matched cohorts, patients given modified-release opioids (n = 347) experienced a higher incidence of opioid-related adverse events overall, compared with those given immediate-release opioids only (20.5%, 71/347 vs. 12.7%, 44/347; difference in proportions 7.8% [95%CI 2.3–13.3%]). Modified-release opioid use was associated with an increased risk of harm when used for acute pain during hospitalisation after total hip or knee arthroplasty.  相似文献   
3.
Renal cell cancer (RCC) represents 2%-3% of all adulthood cancers and is the most common malignant neoplasm of the kidney (90%). In the mid-nineties of the last century, the standard of treatment for patients with metastatic RCC was cytokines. Sunititib and pazopanib were registered in 2007 and 2009, respectively, and have since been the standard first-line treatment for metastatic clear cell RCC (mccRCC). Renal cell cancer is a highly immunogenic tumor with tumor infiltrating cells, including CD8+ T lymphocytes, dendritic cells, natural killer cells (NK) and macrophages. This observation led to the design of new clinical trials in which patients were treated with immunotherapy. With the growing evidence that proangiogenic factors can have immunomodulatory effects on the host’s immune system, the idea of combining angiogenic drugs with immunotherapy has emerged, and new clinical trials have been designed. In the last few years, several therapeutic options have been approved [immunotherapy and immunotherapy/tyrosine kinase inhibitors (TKI)] for the first-line treatment of mccRCC. Nivolumab/ipilimumab is approved for the treatment of patients with intermediate and poor prognoses. Several checkpoint inhibitors (pembrolizumab, nivolumab, avelumab) in combination with TKI (axitinib, lenvatinib, cabozantinib) are approved for the treatment of patients regardless of their International mRCC Database Consortium prognostic group and PD-L1 expression. There is no specific and ideal biomarker that could help in selecting the ideal patient for the appropriate first-line treatment.  相似文献   
4.
Neuroscience and Behavioral Physiology - We present here results from analysis of the formation of brain bioelectrical activity in children and adolescents living in the northern region of Russia...  相似文献   
5.
6.
7.
8.
Microbial co-infections are another primary concern in patients with coronavirus disease 2019 (COVID-19), yet it is an untouched area among researchers. Preliminary data and systematic reviews only show the type of pathogens responsible for that, but its pathophysiology is still unknown. Studies show that these microbial co-infections are hospital-acquired/nosocomial infections, and patients admitted to intensive care units with invasive mechanical ventilation are highly susceptible to it. Patients with COVID-19 had elevated inflammatory cytokines and a weakened cell-mediated immune response, with lower CD4+ T and CD8+ T cell counts, indicating vulnerability to various co-infections. Despite this, there are only a few studies that recommend the management of co-infections.  相似文献   
9.
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号